Objective To investigate the clinical characteristics of primary adult renal sarcoma.Methods A total of 1654 cases with adult renal tumors were treated during 1985 to 2009 in Peking Union Medical College Hospital.Of a...Objective To investigate the clinical characteristics of primary adult renal sarcoma.Methods A total of 1654 cases with adult renal tumors were treated during 1985 to 2009 in Peking Union Medical College Hospital.Of all,17 cases were diagnosed as primary renal sarcoma and underwent radical nephrectomy.The clinical features of 17 such patients were retrospectively analyzed.Results The first symptom of 10(59%) cases in all renal sarcomas was abdominal mass.The pathological diagnosis was leiomyosarcoma(7 cases),rhabdomyosarcoma(2 cases),malignant fibrous histiocytoma(2 cases),low-differentiated sarcoma(2 cases),chromophobe renal cell carcinoma coexisting with liposarcoma(1 case),fibrosarcoma(1 case),embryonic sarcoma(1 case) and leiomyosarcoma(1 case).One patient died of tumor thrombus of the inferior vena cava during surgery.Finally,15 cases were regularly followed up for 4 to 60 months.Till now,1 had tumor-free survival for 9 months,and the other 14 cases died 2-38 months after the operation with a median survival time of 18(range,5-60) months.The median survival time of leiomyosarcoma group was 28(range,11-60) months,and 2 cases of malignant fibrous histiocytoma died 4 and 8 months after the operation respectively.Conclusions The primary renal sarcoma has the clinical symptom similar with advanced renal cell carcinoma and has poor prognosis.Leiomyosarcoma might have relative good prognosis.展开更多
目的探讨影响尸肾移植术后人/肾存活率的危险因素。方法对1984年2月至2003年12月1806例尸肾移植患者的临床资料进行总结,应用Kap lan-M e ier分析计算1、5、10、15和20年人/肾存活率和移植肾半寿期。对可能影响人/肾存活率的各因素,如...目的探讨影响尸肾移植术后人/肾存活率的危险因素。方法对1984年2月至2003年12月1806例尸肾移植患者的临床资料进行总结,应用Kap lan-M e ier分析计算1、5、10、15和20年人/肾存活率和移植肾半寿期。对可能影响人/肾存活率的各因素,如受者性别、年龄、移植时间、移植次数、透析时间、乙型肝炎表面抗原、移植肾功能恢复延迟(DGF)、急性排斥、慢性排斥、感染、高血压、糖尿病和免疫抑制剂等进行Log-Rank单因素分析和Cox多因素回归分析,找出影响人/肾存活率的独立危险因素。结果总体1、5、10、15、20年人存活率分别为92.28%、87.20%、78.60%、63.45%、47.59%;肾存活率分别为84.61%、73.64%、57.31%、46.77%、31.18%;总体移植肾半寿期为(11.94±0.84)年。2001-2003年的1年人/肾存活率达95.51%和91.72%。单因素和多因素分析表明,高龄、DGF、糖尿病、感染、急性排斥和多次移植是影响移植肾存活率的独立危险因素,而前4者是影响患者存活率的独立危险因素。吗替麦考酚酯(骁悉)可显著提高移植肾存活率。结论骁悉等新型免疫抑制剂的应用显著提高了移植肾存活率,积极防治感染、心脑血管疾病等术后并发症是进一步提高人/肾存活率的关键。展开更多
文摘Objective To investigate the clinical characteristics of primary adult renal sarcoma.Methods A total of 1654 cases with adult renal tumors were treated during 1985 to 2009 in Peking Union Medical College Hospital.Of all,17 cases were diagnosed as primary renal sarcoma and underwent radical nephrectomy.The clinical features of 17 such patients were retrospectively analyzed.Results The first symptom of 10(59%) cases in all renal sarcomas was abdominal mass.The pathological diagnosis was leiomyosarcoma(7 cases),rhabdomyosarcoma(2 cases),malignant fibrous histiocytoma(2 cases),low-differentiated sarcoma(2 cases),chromophobe renal cell carcinoma coexisting with liposarcoma(1 case),fibrosarcoma(1 case),embryonic sarcoma(1 case) and leiomyosarcoma(1 case).One patient died of tumor thrombus of the inferior vena cava during surgery.Finally,15 cases were regularly followed up for 4 to 60 months.Till now,1 had tumor-free survival for 9 months,and the other 14 cases died 2-38 months after the operation with a median survival time of 18(range,5-60) months.The median survival time of leiomyosarcoma group was 28(range,11-60) months,and 2 cases of malignant fibrous histiocytoma died 4 and 8 months after the operation respectively.Conclusions The primary renal sarcoma has the clinical symptom similar with advanced renal cell carcinoma and has poor prognosis.Leiomyosarcoma might have relative good prognosis.
文摘目的探讨影响尸肾移植术后人/肾存活率的危险因素。方法对1984年2月至2003年12月1806例尸肾移植患者的临床资料进行总结,应用Kap lan-M e ier分析计算1、5、10、15和20年人/肾存活率和移植肾半寿期。对可能影响人/肾存活率的各因素,如受者性别、年龄、移植时间、移植次数、透析时间、乙型肝炎表面抗原、移植肾功能恢复延迟(DGF)、急性排斥、慢性排斥、感染、高血压、糖尿病和免疫抑制剂等进行Log-Rank单因素分析和Cox多因素回归分析,找出影响人/肾存活率的独立危险因素。结果总体1、5、10、15、20年人存活率分别为92.28%、87.20%、78.60%、63.45%、47.59%;肾存活率分别为84.61%、73.64%、57.31%、46.77%、31.18%;总体移植肾半寿期为(11.94±0.84)年。2001-2003年的1年人/肾存活率达95.51%和91.72%。单因素和多因素分析表明,高龄、DGF、糖尿病、感染、急性排斥和多次移植是影响移植肾存活率的独立危险因素,而前4者是影响患者存活率的独立危险因素。吗替麦考酚酯(骁悉)可显著提高移植肾存活率。结论骁悉等新型免疫抑制剂的应用显著提高了移植肾存活率,积极防治感染、心脑血管疾病等术后并发症是进一步提高人/肾存活率的关键。
